+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis



Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis



Infection and Immunity 69(4): 2223-2229



Pseudomonas aeruginosa is a significant human pathogen, and no vaccine is commercially available. Passive antibody prophylaxis using monoclonal antibodies (MAb) against protective P. aeruginosa epitopes is an alternative strategy for preventing P. aeruginosa infection, but mouse MAb are not suitable for use in humans. Polyclonal human antibodies from multiple donors have variable antibody titers, and human MAb are difficult to make. We used immunoglobulin-inactivated transgenic mice reconstituted with megabase-size human immunoglobulin loci to generate a human MAb against the polysaccharide (PS) portion of the lipopolysaccharide O side chain of a common pathogenic serogroup of P. aeruginosa, 06ad. The anti-PS human immunoglobulin G2 MAb made from mice immunized with heat-killed P. aeruginosa was specific for serogroup 06ad pseudomonas. The MAb was highly opsonic for the uptake and killing of P. aeruginosa by human polymorphonuclear leukocytes in the presence of human complement. In addition, 25 microg of the MAb protected 100% of neutropenic mice from fatal P. aeruginosa sepsis. DNA sequence analysis of the genes encoding the MAb revealed V(H)3 and Vkappa2/A2 variable-region genes, similar to variable-region genes in humans immunized with bacterial PS and associated with high-avidity anti-PS antibodies. We conclude that human MAb to P. aeruginosa made in these transgenic mice are highly protective and that these mice mimic the antibody response seen in humans immunized with T-cell-independent antigens such as bacterial PS.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010767246

Download citation: RISBibTeXText

PMID: 11254577

DOI: 10.1128/iai.69.4.2223-2229.2001


Related references

Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23(25): 3264-3271, 2005

Human monoclonal antibody against Pseudomonas aeruginosa LPS derived from transgenic XenoMouseTM mice is opsonic and highly protective in the neutropenic mouse model of sepis. Clinical Infectious Diseases 31(1): 213, 2000

Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. Fems Microbiology Immunology 2(5-6): 263-268, 1990

Opsonic killing and mouse protective activity of monoclonal mab and polyclonal human immunoglobulin g m and a specific for pseudomonas aeruginosa lipopolysaccharide lps. Abstracts of the Annual Meeting of the American Society for Microbiology 88: 49, 1988

Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies. Infection and Immunity 5(5): 775-782, 1972

Murine monoclonal antibodies against core determinants of international type 6 pseudomonas aeruginosa lipopolysaccharide are opsonic and protective. Abstracts of the Annual Meeting of the American Society for Microbiology 85: 41, 1985

Effect of human monoclonal antibody against O-antigen and core-antigen of lipopolysaccharide on gut-derived Pseudomonas aeruginosa sepsis in mice. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 66, 2003

Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice. Clinical and Diagnostic Laboratory Immunology 6(4): 537-541, 1999

Contribution of humoral and cellular factors to the resistance to experimental infection by pseudomonas aeruginosa in mice part 2 opsonic agglutinative and protective capacities of immuno globulin g anti pseudomonas antibodies. Infection & Immunity 5(5): 775-782, 1972

Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide. Infection and Immunity 66(9): 4137-4142, 1998

Opsonic and protective monoclonal antibodies mab directed to pseudomonas aeruginosa lps fail to prevent chronic pa pneumonia. Pediatric Research 25(4 Part 2): 190A, 1989

Hem agglutinating opsonic and protective antibodies to pseudomonas aeruginosa in pooled human immuno globulin g modified for intra venous use in man. Clinical Research 29(2): 394A, 1981

A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide. Infection and Immunity 59(1): 1-6, 1991

Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infection and Immunity 68(4): 1820-1826, 2000

Generation and protective activities of human monoclonal antibodies against Pseudomonas aeruginosa. Nihon Rinsho. Japanese Journal of Clinical Medicine 49(10): 2441-2445, 1991